Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

被引：5

作者：

Mueller D. ^{[1
]}

Gandjour A. ^{[2
]}

机构：

[1] Institute for Health Economics and Clinical Epidemiology, University Hospital of Cologne (AöR), D-50935 Köln

[2] Pennington Biomedical Research Center, Louisiana State University, Louisiana

来源：

Applied Health Economics and Health Policy | 2011年 / 9卷 / 4期

关键词：

Alendronic-acid; Budget-impact-analysis; Cost-utility; Postmenopausal-; osteoporosis; Radiography;

D O I：

10.2165/11587360-000000000-00000

中图分类号：

学科分类号：

摘要：

Background: The aging of the population is likely to increase the number of osteoporosis-related fractures, such as hip fractures, and hence the economic burden for society. Therefore, strategies to identify women at increased risk are of major interest. Objective: The aim of this study was to determine the cost effectiveness of preventive services for osteoporosis, comparing secondary plus tertiary prevention (SP/TP) versus tertiary prevention (TP) alone in post-menopausal women in Germany. Methods: A cost-utility analysis and a budget-impact analysis were performed from the perspective of the German statutory health insurance (SHI). A Markov model simulated costs and benefits discounted at 3% over a lifetime horizon. Results: Cost effectiveness of TP compared with no screening was €669, €477 and €385 per QALY for women aged 60, 70 and 80 years, respectively (year 2010 values). In women aged 50 years, TP dominated no prevention. Cost effectiveness of SP/TP compared with TP was €4543, €19 791, €8670 and €3368 for women aged 50, 60, 70 and 80 years, respectively. SP/TP resulted in additional costs of €109 million or 0.10% of the SHIs annual budget (TP alone = €8 million). Conclusion: Compared with TP, a strategy based on SP/TP appears to be more expensive but more effective in each age group. Given that cost effectiveness seems acceptable, allocation of resources to SP/TP to decrease postmenopausal osteoporotic fracture risk may be justified. © 2011 Adis Data Information BV. All rights reserved.

引用

页码：259 / 273

页数：14

共 70 条

[1]

Prevention and management of osteoporosis: Report of a WHO Scientific Group, WHO Technical Report Series no. 921

[2]

Dolan P., Torgerson D.J., The cost of treating osteoporotic fractures in the United Kingdom female population, Osteoporosis International, 8, 6, pp. 611-617, (1998)

[3]

Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025, Journal of Bone and Mineral Research, 22, 3, pp. 465-475, (2007)

[4]

Dequeker J., Strategies for prevention and treatment of osteoporosis at the primary, secondary, and tertiary level in Leuven, Belgium, Clin Calcium, 11, 4, pp. 477-488, (2001)

[5]

Prophylaxe, Diagnostik und Therapie der Osteoporose. S3-Leitlinie des Dachverbandes der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften, (2006)

[6]

NOFs Clinicians Guide to Prevention and Treatment of Osteoporosis

[7]

Osteoporosis: Secondary Prevention. the Clinical Effectiveness of Technologies for the Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women, (2005)

[8]

Luhmann D.K., Use of bone densitometry in the framework of prevention and therapy of osteoporosis: Example of a systematic evaluation (health technology assessment), Z Arztl Fortbild Qualitatssich, 94, 6, pp. 475-81, (2000)

[9]

Zusammenfassender Bericht des Arbeitsausschusses Ärztliche Behandlung des Bundesausschusses der Ärzte und Krankenkassen Über Die Beratungen des Jahres 1999 Zur Bewertung der Osteodensitometrie GemäX y135 Abs. 1 SGB v, (2000)

[10]

Mueller D., Weyler E., Gandjour A., Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis, PharmacoEconomics, 26, 6, pp. 513-536, (2008)

← 1 2 3 4 5 6 7 →